Erratum: Ochnaflavone inhibits TNF‐α‐induced human VSMC proliferation via regulation of cell cycle,ERK1/2, and MMP‐9. S.‐J. Suh,U.‐H. Jin,S.‐H. Kim,H.‐W. Chang,J.‐K. Son,S.H. Lee,K.‐H. Son,C.‐H. Kim

During the corresponding author's transfer from Dongguk University to Sungkyunkwan University in March 2006, data from the previous University was transferred to the corresponding author's new computer. During this data transfer there was a mixing of EMSA data from experiments involving Quercetin (QC), Ochnaflavone (OC), Tanshinone (TS), Crytotanshinone (CT), BMK, and natural extracts. The mixed EMSA data was inadvertently incorporated in more than one publication. Figure 6 has been corrected to new data with re‐confirmation. J. Cell. Biochem. 108: 337, 2009. © 2009 Wiley‐Liss, Inc.

6. Effect of OC on the TNF‐α‐induced DNA binding activities of MMP‐9, NF‐κB, and AP‐1 motif in HASMC. Cells were pretreated with indicated OC for 40 min in serum‐free medium, were incubated with TNF‐α (100 ng/ml) for 24 h. Nuclear extracts were analyzed by EMSA for the activated NF‐κB (A) and AP‐1 (B) using radiolabeled oligonucleotide probes, respectively. Indicated values are means of three triplicate experiments.     

Zur „Genauigkeit”︁ bei J. G. Mendel

When taking into account J. G. MENDEL's observed frequencies and comparing them with those noted down by BATESON, CORRENS and DARBISHIRE no ?striking”? preciseness in accordance with the statement made by F. WELLING is to be noticed statistically. By means of the four-field table measure K speculations as to a ?too precise”? indication of frequencies are to be refuted in an easy way.     

Enantiomeric assay of escitalopram S(+)‐enantiomer and its “in‐process impurities” using two different techniques

The enantiomeric purity of escitalopram oxalate ESC and its “in‐process impurities,” namely, ESC‐N‐oxide, ESC‐citadiol, and R(?)‐enantiomer were studied in drug substance and products using high‐performance liquid chromatography (HPLC)‐UV (Method I), synchronous fluorescence spectroscopy (SFS) (Method IIA), and first derivative SFS (Method IIB). Method I describes as an isocratic HPLC‐UV for the direct resolution and determination of enantiomeric purity of ESC and its “in‐process impurities.” The proposed method involved the use of α_l‐acid glycoprotein (AGP) chiral stationary phase. The regression plots revealed good linear relationships of concentration range of 0.25 to 100 and 0.25 to 10 μg mL^?1 for ESC and its impurities. The limits of detection and quantifications for ESC were 0.075 and 0.235 μg mL^?1, respectively. Method II involves the significant enhancement of the fluorescence intensities of ESC and its impurities through inclusion complexes formation with hydroxyl propyl‐β‐cyclodextrin as a chiral selector in Micliavain buffer. Method IIA describes SFS technique for assay of ESC at 225 nm in presence of its impurities: R(?)‐enantiomer, citadiol, and N‐oxide at ?λ of 100 nm. This method was extended to (Method IIB) to apply first derivative SFS for the simultaneous determination of ESC at 236 nm and its impurities: the R(?)‐enantiomer, citadiol, and N‐oxide at 308, 275, and 280 nm, respectively. Linearity ranges were found to be 0.01 to 1.0 μg mL^?1 for ESC and its impurities with lower detection and quantification limits of 0.033/0.011 and 0.038/0.013 μg mL^?1 for SFS and first derivative synchronous fluorescence spectra (FDSFS), respectively. The methods were used to investigate the enantiomeric purity of escitalopram.     

Stereoselective synthesis of fully protected (2S,4S,6S)‐2‐amino‐6‐hydroxy‐4‐methyl‐8‐oxodecanoic acid (AHMOD)

The stereocontrolled synthesis of fully protected (2S,4S,6S)‐2‐amino‐6‐hydroxy‐4‐methyl‐8‐oxodecanoic acid was accomplished using a glutamate derivative as starting material. The key steps of this stereochemical synthetic pathway involved an Evans asymmetric alkylation, a Sharpless asymmetric epoxidation, and a Grignard reaction. Copyright © 2012 European Peptide Society and John Wiley & Sons, Ltd.